Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Nov 13 - Nov 18
It has been shown in clinical studies to produce significant weight loss results, with many patients losing a notable percentage of their body weight when used as part of a comprehensive weight loss plan
In 2008, the adverse cardiovascular outcomes observed in trials involving tolbutamide and rosiglitazone prompted mandates that all antidiabetic agents meet cardiovascular safety endpoints
NPH is the only insulin that can be mixed in the same syringe with all currently available bolus injectable insulin products
This caloric reduction is the primary driver to lose weight
US$ 20.69
US$ 29.41
US$ 20.98
US$ 23.99
US$ 21.49
